

## WYETH

### REPORT ON EXPORTING ANIMAL TESTING

This Proposal is submitted by People for the Ethical Treatment of Animals.

RESOLVED, that the Board report to shareholders on the rationale for increasingly exporting the Company's animal experimentation to countries which have either nonexistent or substandard animal welfare regulations and little or no enforcement. Further, shareholders request that the report include information on the extent to which Wyeth requires adherence to U.S. animal welfare standards at facilities in foreign countries.

***Supporting Statement:***

Our Company has posted guidelines on its Web site entitled *Animal Welfare Policy*. The Company has publicly stated that "all animal use at Wyeth Research must be conducted in a humane and scientifically sound manner."<sup>1</sup> Additionally, the *Animal Welfare Policy* provides and requires that:

- Animal care and use programs be headed by specially trained veterinarians and professionals who are responsible for implementing sound animal management practices;
- Pain and distress in research animals be avoided or minimized and, when unavoidable, the administration of appropriate analgesics, anesthetics or other non-pharmacologic approaches will be used;
- Humane and appropriate methods of euthanasia be used; and

---

<sup>1</sup> <http://www.wyeth.com/aboutwyeth/citizenship/animalwelfare>

- All personnel involved in animal care must have received proper animal care and use training.

But as reported in *Forbes* magazine the rationale for outsourcing animal testing to China, the leading location for such testing, is that "scientists are cheap, lab animals plentiful and pesky protesters held at bay."<sup>2</sup> Similarly, *Business Week* reported on the pharmaceutical industry's increasing reliance on outsourcing testing to India, China, and Russia.<sup>3</sup> DrugResearcher.com published an article entitled "*China luring preclinical players*," further highlighting the industry's pursuit of outsourcing.<sup>4</sup> Wyeth has apparently succumbed to the outsourcing frenzy and has a presence in China, and is conducting preclinical trials in India.<sup>5</sup>

As recent media reports of safety scandals and product recalls have made abundantly clear, standards for products exported from China to the U.S. are lacking. Shareholders deserve to understand why animal testing is being moved to foreign countries, such as China and India. Moreover, our Company should report on the steps that are being taken to assure shareholders that animal testing conducted in other countries is held to at least the same animal welfare standards as animal testing conducted in the U.S.

We urge shareholders to support this resolution.

---

<sup>2</sup> "Comparative Advantage"; *Forbes*, p. 76 Vol. 178 No. 10 (Nov. 13, 2006)

<sup>3</sup> "The Future of Outsourcing"; *Business Week*, (Jan. 30, 2006)

<sup>4</sup> "China luring preclinical players"; DrugResearcher.com (Oct. 10, 2007)

<sup>5</sup> "Wyeth 'learns and confirms' in India"; ChemEurope.com at <http://www.chemeuropa.com/articles/e/55869/>